Tirzepatide linked to lower risk of papilledema and vision loss in intracranial hypertension study

A retrospective study of patients with idiopathic intracranial hypertension (IIH) found that those treated with tirzepatide were substantially less likely to develop papilledema or vision problems than similar patients who received standard care ^[1]. The paper was published February 13, 2025, in the journal Endocrinology, Diabetes & Metabolism ^[1].

The analysis drew on the TriNetX Global Health Research Network, using records through November 2024 ^[1]. Researchers compared 193 patients with IIH who had been exposed to tirzepatide with 193 patients with IIH who received standard care, matching the groups with a statistical technique called propensity score matching, which tries to balance them on characteristics that could affect results ^[1]. Over 24 months, the tirzepatide group had a 68 percent lower risk of papilledema — swelling of the optic disc, a sign of pressure inside the skull — and a 73.9 percent lower risk of visual disturbance or blindness ^[1].

Tirzepatide is a dual GIP/GLP-1 receptor agonist sold as Mounjaro and Zepbound. The researchers set out to test whether activating both of those hormone receptors might help in IIH, a neurological disorder marked by elevated pressure inside the skull that mainly affects obese women of reproductive age ^[1]. The paper notes that GLP-1 receptor agonists — the class that includes semaglutide, sold as Ozempic, Wegovy and Rybelsus — have shown promise in IIH management, while tirzepatide's potential in the condition had not been explored ^[1].

Headache frequency and treatment resistance were also listed as outcomes in the study; results for those have not been reported.

What the study can and cannot show

The findings are observational, so they cannot prove that tirzepatide caused the lower risk of eye problems. Patients who receive a newer drug may differ from those who do not in ways that matching cannot capture, and the study was not randomized ^[1].

The outcomes were based on diagnosis codes in a large health records network rather than standardized eye examinations ^[1]. That approach can miss cases or misclassify them, which matters for a condition where the key signs are found by looking at the back of the eye.

How the results compare with semaglutide or other GLP-1 drugs in IIH has not been reported. No head-to-head study of the two drug classes in this condition appears in the paper ^[1].

Why it matters for patients

IIH can cause persistent headaches and, in serious cases, permanent vision loss, so any signal that a treatment lowers that risk draws attention. This study suggests an association between tirzepatide and fewer recorded cases of papilledema and visual disturbance, but it does not establish that the drug prevents vision loss ^[1].

Tirzepatide is not approved to treat IIH. Nothing in the study changes the Food and Drug Administration labeling for Mounjaro or Zepbound, and no regulatory action on an IIH indication has been disclosed ^[1]. The people studied all had IIH, so the results say nothing about eye risk in people taking tirzepatide for weight loss or type 2 diabetes who do not have the condition.

For patients with IIH who are already taking tirzepatide, or considering a GLP-1 or dual-agonist medication, the practical question is what this kind of evidence means for their own care. The study does not address how often eye exams should be done, whether treatment should be started or stopped, or how the drug interacts with other IIH therapies. Those decisions have not been tested in a randomized trial of tirzepatide in IIH, and the paper does not offer guidance on them ^[1].

What happens next

No randomized controlled trial of tirzepatide in idiopathic intracranial hypertension has been announced or reported, and no company submission to regulators for an IIH indication has been disclosed. The 24-month results come from one retrospective analysis of insurance claims and health records through November 2024 ^[1].